GlobalData

There is no shortage of candidates to help with COVID-19, but what is lacking right now is data on their efficacy

This could mean accelerated access of multiple novel therapies and vaccines for Indian patients

The impact of approved therapies replacing generic off-label treatments will be the main driver of growth in the 5GM GvHD market

AstraZeneca’s AZD-1222 and Moderna’s mRNA-1273 are currently the most promising vaccine candidates, it states

The ongoing early study only requires 30 COVID-19 cases to detect vaccine efficacy, which is much too small to be sure of…

AI start-ups are helping pharma companies to digitally bridge the gap between thousands of repurposed drug molecules, clinical…

Indian pharma companies are more likely to engage in contract/excess capacity API manufacture than companies in the other small…

The number of trials that have been impacted by slow enrollment has increased by 13.9 per cent

There are 13 Indian organisations working on COVID-19 vaccine development

Big pharma companies are searching for innovative biotechs to invest in the rare diseases space